About
REINVENTING HOW HEALTHCARE PROFESSIONALS AND PATIENTS MANAGE PAIN
Virpax Pharmaceuticals is committed to developing non-addictive product candidates that manage pain and its complexities, while providing treatment options and minimizing risks to patients and society. By combining selected drug compounds with our cutting‑edge delivery systems, we strive to maximize our products’ capabilities and successfully bring them to market. We believe our proprietary delivery systems will reinvent how patients and prescribers manage pain worldwide.
Non-addictive products
We are advancing proprietary drug delivery platforms that will address an urgent need for non-addictive treatment alternatives in the management of pain and CNS disorders. Our Molecular Envelope Technology (MET) and liposomal hydrogel technology will significantly improve our drug delivery characteristics by directly targeting pain and CNS Disorder symptoms at their source.
CNS Growth Opportunities
Our MET platform is being used to grow our Central Nervous System (CNS) disorder pipeline. The current product candidates include Post Traumatic Stress Disorder (PTSD), and Rare Pediatric Epilepsy. We believe the MET may be used to deliver molecules to manage symptoms related to other neurodegenerative and neurotransmission disorders, including Parkinson’s, Alzheimer’s, Cancer Cachexia (multi-organ systemic inflammation), and Migraines.
“We remain committed to working with sponsors, patients, and other stakeholders to advance safe and effective treatments for patients when new therapies are submitted to us for evaluation… Our focus is heightened when that unmet medical need involves a progressive and fatal disease.”
U.S. Food and Drug Administration
JULY 29, 2021
Prescribers, regulators, and patients all seek non-addictive treatment options to combat the opioid epidemic.
FDA takes steps aimed at fostering development of non-addictive alternatives to opioids for acute pain management lasting up to 30 days, in response to some form of tissue injury, such as trauma or surgery.
February 2022
The accelerating development of new treatments and devices are top six on the FDA priority list.
February 2022
We are continuously strengthening our worldwide patents in the development of non-addictive treatments for pain and degenerative neurological disorders.
We are seeking FDA approval for a robust pipeline of product candidates that will radically change how clinicians prescribe pain and CNS disorder therapies in the future.
